Pegylated interferon/ribavirin-associated sudden hearing loss in a patient with chronic hepatitis C in Brazil

AUTOR(ES)

Mendes-Corrêa, Maria Cassia Jacintho, Bittar, Roseli Saraiva Moreira, Salmito, Norma, Oiticica, Jeanne

FONTE

Brazilian Journal of Infectious Diseases

DATA DE PUBLICAÇÃO

2011-02

RESUMO

Sudden hearing loss is defined as a sensorineural hearing loss, equal to or greater than 30 dB, at three or more consecutive frequencies, which takes place within 72 hours. Both peginterferon and ribavirin are well-known to be associated with significant adverse effects, but sudden hearing loss is uncommon. We report a 65-year-old male patient who developed sudden-onset hearing loss during combination therapy with pegylated interferon-alpha and ribavirin for chronic hepatitis C. Peginterferon and ribavirin may cause sudden hearing loss that may not recover after discontinuation of therapy. Immediate treatment for all possible etiologies is essential, along with targeted investigations and early referral for an Ear, Nose and Throat specialist. Physicians should be aware of the possible ototoxic effects of peginterferon and ribavirin combination therapy requiring appropriate surveillance.

Documentos Relacionados

• DEPRESSIVE EPISODE INCIDENCE IN PATIENTS WITH CHRONIC HEPATITIS C TREATED WITH PEGYLATED INTERFERON AND RIBAVIRIN
• Extended treatment with interferon and ribavirin in a hemodialysis patient with chronic hepatitis C
• Dilated cardiomyopathy and hypothyroidism associated with pegylated interferon and ribavirin treatment for chronic hepatitis C: case report and literature review
• Combined pegylated interferon and ribavirin for the management of chronic hepatitis C in a prison setting
• Expectoration of large bronchial casts secondary to the treatment of chronic hepatitis c with pegylated interferon and ribavirin